The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis

Cancer-associated thrombosis (CAT) carries significant morbidity and mortality. Low-molecular-weight heparin (LMWH) remains the standard of care, with recent systematic studies suggesting the efficacy and safety of rivaroxaban in the treatment of CAT. Uncertainty, however, remains regarding rivaroxa...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Mouhand F. H., ElShafei, Mohamad Nabil, Ahmed, Mohamed Badie, Abdalla, Lina O., Ahmed, Israa, Elzouki, Abdel-Naser, Danjuma, Mohammed ibn-mas’ud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930650/
https://www.ncbi.nlm.nih.gov/pubmed/33651658
http://dx.doi.org/10.1177/1076029620940046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930650/
https://www.ncbi.nlm.nih.gov/pubmed/33651658
http://dx.doi.org/10.1177/1076029620940046

Ejemplares similares